Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TALi Digital Limited (TD1.AX)
Camberwell, VIC, AU
TALi Digital Limited is an Australian digital health firm dedicated to improving cognitive function and behavior through its diagnostic and therapeutic offerings. The company provides TALi DETECT, an evidence-based digital screening program lasting 20-30 minutes, which utilizes cognitive assessments to gauge a child's attention skills relative to their peers. Complementing this is TALi TRAIN, a digital cognitive training solution designed to enhance selective attention and numeracy, and in certain cases, alleviate inattentive and hyperactive behaviors in children. The company maintains a significant licensing agreement with Akili Interactive Labs, Inc. for pediatric cognitive products. Founded in 2004, the enterprise, headquartered in Camberwell, was formerly known as Novita Healthcare Limited until its name change in December 2019.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.79% | +9.62% | +35.71% | +11.76% | -40.00% | +1.79% | -43.00% | -62.00% | -98.23% | -95.65% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%-40.6% Q4'25: +335.8% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+77.8% ★ Q4'25: +85.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-47,006.7% Q4'25: -747.1% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-59,973.9% Q4'25: -863.2% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%-72.9% Q4'25: -224.0% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+1.0% Q4'25: +36.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
|---|---|---|---|---|
| Revenue |
287.0K
est: 203.0K (+41.4%)
|
891.0K
est: 203.0K (+338.9%)
|
—
est: 1.42M (-100.0%)
|
398.0K
est: 1.93M (-79.4%)
|
| EBITDA |
-15.13M
est: -203.0K (-7,354.2%)
|
-35.89M
est: -199.0K (-17,934.2%)
|
-35.86M
est: -252.63M (+85.8%)
|
-41.09M
est: -49.16M (+16.4%)
|
| EBIT |
-15.21M
est: -203.0K (-7,392.6%)
|
-36.07M
est: -199.0K (-18,027.1%)
|
-36.12M
est: -252.63M (+85.7%)
|
-41.33M
est: -49.16M (+15.9%)
|
| Net Income |
-15.22M
est: -33.70M (+54.8%)
|
-36.09M
est: -36.07M (-0.1%)
|
-36.22M
est: -252.63M (+85.7%)
|
-41.49M
est: -49.16M (+15.6%)
|
| SGA |
5.57M
est: 46.67M (-88.1%)
|
8.27M
est: 46.67M (-82.3%)
|
8.42M
est: 326.66M (-97.4%)
|
7.27M
est: 443.33M (-98.4%)
|
| EPS |
-71.00
est: -1.01 (-6,910.6%)
|
-108.00
est: -1.08 (-9,884.6%)
|
-109.00
est: -0.91 (-11,848.9%)
|
-74.00
est: -0.39 (-18,945.7%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rose | Executive Officer | 167.2K | male |
| David Lionel Brookes FACRRM FAICD MBBS | Chair & Executive Director | 52.5K | — |
| Paul McKeon | Investor Relations Manager | — | — |
| Timothy Luscombe | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TD1.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
